Searching for perfect sleep: The continuing evolution of GABAA receptor modulators as hypnotics

Journal of Psychopharmacology

Volumn 24, Issue 11, 2010, Pages 1601-1612

  Nutt, David J ^a   Stahl, Stephen M ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

benzodiazepines; eszopiclone; GABA; hypnotics; zaleplon; zolpidem; zopiclone

Indexed keywords

4 AMINOBUTYRIC ACID A ALPHA1 RECEPTOR; 4 AMINOBUTYRIC ACID A ALPHA2 RECEPTOR; 4 AMINOBUTYRIC ACID A ALPHA3 RECEPTOR; 4 AMINOBUTYRIC ACID A ALPHA5 RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR; ESZOPICLONE; HYPNOTIC AGENT; RECEPTOR SUBTYPE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ARTICLE; COMORBIDITY; CONVALESCENCE; DEPRESSION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; SEDATION; SLEEP; SLEEP TIME; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COMORBIDITY; DRUG THERAPY, COMBINATION; HUMANS; HYPNOTICS AND SEDATIVES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GABA-A; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 77955154079     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106927     Document Type: Article

References (106)

1. Asnis GM, Chakraburtty A., DuBoff EA, et al. (1999) Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiat 60: 668-676.
2. Atack JR, Hutson PH, Collinson N., et al. (2005) Anxiogenic properties of an inverse agonist selective for alpha 3 subunit-containing GABA a receptors. Brit J Pharmacol 144: 357-366.
3. Atack JR, Wafford KA, Tye SJ, et al. (2006) TPA023 (7-(1,1-dimethylethyl) -6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4, 3-b)pyridazine). an agonist selective for alpha 2- and alpha 3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316: 410-422.
4. Bailey JE, Papadopoulos A., Seddon K., Nutt DJ (2009) A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety. J Psychopharmacol 23: 117-122.
5. Bocca ML, Denise P. (2000) Residual effects of hypnotics on disengagement of spatial attention. J Psychopharmacol 14: 401-405.
6. Boyle J., Trick L., Johnsen S., Roach J., Rubens R. (2008) Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 23: 385-397.
7. Browne SH, Kang J., Akk G., et al. (2001) Kinetic and pharmacological properties of GABA(A) receptors in single thalamic neurons and GABA(A) subunit expression. J Neurophysiol 86: 2312-2322.
8. Brunello N., Bettica P., Amato D., Maier G., Nutt D. (2008) Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone. Eur Neuropsychopharm 18: S581.
9. Brunello N., Cooper J., Bettica P., Maier G., Nutt D. (2009) Differential pharmacological profiles of the GABAA receptor modulators zolpidem, zopiclone, eszopiclone, and (S)-desmethylzopiclone. Abstract Presented at the World Psychiatric Association International Congress (WPA-Florence).
10. Carlson JN, Haskew R., Wacker J., Maisonneuve IM, Glick SD, Jerussi TP (2001) Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol 415: 181-189.
11. Collinson N., Kuenzi FM, Jarolimek W., et al. (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 22: 5572-5580.
12. Crestani F., Martin JR, Möhler H., Rudolph U. (2000) Mechanism of action of the hypnotic zolpidem in vivo. Brit J Pharmacol 131: 1251-1254.
13. Dawson GR, Maubach KA, Collinson N., et al. (2006) An inverse agonist selective for alpha 5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther 316: 1335-1345.
14. de Haas SL, de Visser SJ, van der Post JP, et al. (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 21: 374-383.
15. Dias R., Sheppard WF, Fradley RL, et al. (2005) Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25: 10682-10688.
16. Doble A., Martin IL, Nutt DJ (2004) Calming the Brain: Benzodiazepines and Related Drugs from Laboratory to Clinic. London: Martin Dunitz Limited.
17. Dockhorn RJ, Dockhorn DW (1996) Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 19: 333-340.
18. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43: 227-238.
19. Ebert B., Wafford KA, Deacon S. (2006) Treating insomnia: current and investigational pharmacological approaches. Pharmacol Therapeut 112: 612-629.
20. Elie R., Ruther E., Farr I., Emilien G., Salinas E. (1999) Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon clinical study group. J Clin Psychiat 60: 536-544.
21. Fava M., Asnis G., Shrivastava R., et al. (2007) Improved Insomnia Symptoms and Next-day Functioning in Patients with Comorbid Insomnia and Generalized Anxiety Disorder Following Concomitant Zolpidem Extended-release 12.5 mg and Escitalopram Treatment. Presented at 46th Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, FL, USA, December 9-13, 2007.
22. Fava M., Asnis G., Shrivastava R., et al. (2008) Zolpidem Extended-release 12.5 mg, Co-administered with Escitalopram, Improves Insomnia in Patients with Comorbid Insomnia and Major Depressive Disorder. Presented at the American Psychiatric Association (APA) 161st Annual Meeting, Washington, DC. May 3-8, 2008.
23. Fava M., McCall WV, Krystal A., et al. (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiat 59: 1052-1060.
24. Fernandez C., Alet P., Davrinche C., et al. (2002) Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. J Pharm Pharmacol 54: 335-340.
25. Fernandez C., Maradeix V., Gimenez F., Thuillier A., Farinotti R. (1993) Pharmacokinetics of zopiclone and its enantiomers in caucasian young healthy volunteers. Drug Metab Dispos 21: 1125-1128.
26. Fiorelli R., Rudolph U., Straub CJ, Feldon J., Yee BK (2008) Affective and cognitive effects of global deletion of alpha 3-containing Gamma-aminobutyric Acid-A receptors. Behav Pharmacol 19: 582-596.
27. Fleck MW (2002) Molecular actions of (S)-desmethylzopiclone (SEP-174559). an anxiolytic metabolite of zopiclone. J Pharmacol Exp Ther 302: 612-618.
28. Fry J., Scharf M., Mangano R., Fujimori M. (2000) Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 15: 141-152.
29. Gao B., Fritschy JM, Benke D., Mohler H. (1993) Neuron-specific expression of GABAA-receptor subtypes: differential association of the alpha 1- and alpha 3-subunits with Serotonergic and GABAergic neurons. Neuroscience 54: 881-892.
30. Harrison NL (2007) Mechanisms of sleep induction by GABAA receptor agonists. J Clin Psychia 68 (Suppl 5). 6-12.
31. Hevers W., Lüddens H. (1998) The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol 18: 35-86.
32. Holbrook AM, Crowther R., Lotter A., Cheng C., King D. (2000) Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Ass J 162: 225-233.
33. Isawa S., Suzuki M., Uchiumi M., Murasaki M. (2000) The effect of zolpidem and zopiclone on memory. Nihon Shinkei Seishin Yakurigaku Zasshi 20: 61-69.
34. Jansson-Fröjmark M., Lindblom K. (2008) A Bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. J Psychosom Res 64: 443-449. (Pubitemid 351417913)
35. Julou L., Blanchard JC, Dreyfus JF (1985) Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacology, Biochemistry and Behavior 23: 653-659.
36. Kales A. (1990) Benzodiazepine hypnotics and insomnia. Hospital Practice (Office Edition) 25 (Suppl 3). 7-21 (discussion 22-23 ).
37. King Pharmaceuticals. (2006) Sonata (Zaleplon) Capsules Prescribing Information. Bristol, TN: King Pharmaceuticals, March 2006.
38. Kopp C., Rudolph U., Löw K., Tobler I. (2004) Modulation of rhythmic brain activity by diazepam: GABAA receptor subtype and state specificity. Proceedings of the National Academy of Science USA 101: 3674-3679.
39. Krystal AD, Walsh JK, Laska E., et al. (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26: 793-799.
40. Krystal A., Ancoli-Israel S., McCall WV, et al. (2008 b) 12-week study of eszopiclone in elderly out-patients with primary insomnia: effects of treatment discontinuation. Euro Neuropsychopharmacol 18: S517.
41. Krystal A., Ancoli-Israel S., McCall WV, et al. (2008 c) The efficacy of 12 weeks of eszopiclone treatment in elderly patients with primary insomnia: effect on daytime function. Eur Neuropsychopharmacol 18: S517.
42. Krystal AD, Erman M., Zammit GK, Soubrane C., Roth T. on behalf of the ZOLONG Study Group (2008 a) Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: A 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 31: 79-90.
43. Krystal AD, Fava M., Rubens R., et al. (2007) Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. Journal of Clinical Sleep Medicine 3: 48-55.
44. Langen B., Rundfeldt C. (2007) ELB139 An agonist at the benzodiazepine binding site increases 5-HT in the striatum and prefrontal cortex of rats: a microdialysis study. Pharmacology, Biochemistry and Behavior 86: 79-85.
45. Licata SC, Platt DM, Cook JM, Sarma PV, Griebel G., Rowlett JK (2005) Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 (6-fluoro-9-methyl-2-phenyl-4- (pyrrolidin-1-Yl-carbonyl)-2,9-dihydro-1H-pyridol(3,4-B)indol-1-one). J Pharmacol Exp Ther 313: 1118-1125.
46. Lingford-Hughes A., Hume SP, Feeney A., et al. (2002) Imaging the GABA-benzodiazepine receptor subtype containing the alpha 5-subunit in vivo with (11C)Ro15 4513 positron emission tomography. J Cerebr Blood F Met 22: 878-889.
47. Löw K., Crestani F., Keist R., Benke D., Brünig I., Benson JA, Fritschy J-M., Rülicke T., Bluethmann H., Möhler H., Rudolph W. (2000) Science 290: 131-134.
48. Mamelak M., Buck L., Csima A., Price V., Smiley A. (1987) Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction. Sleep 10 (Suppl 1). 79-87.
49. Mathiasen LS, Rodgers RJ, Mirza NR (2007) Comparative effects of nonselective and subtype-selective gamma-aminobutyric acida receptor positive modulators in the rat-conditioned emotional response test. Behav Pharmacol 18: 191-203.
50. McCall WV, Erman M., Krystal AD, et al. (2006) A polysomnography study of eszopiclone in elderly patients with insomnia. Cur Med Res and Opi 22: 1633-1642.
51. McKernan RM, Rosahl TW, Reynolds DS, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha 1 subtype. Nat Neurosci 3: 587-592.
52. McMahon LR, Jerussi TP, France CP (2003) Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys. Psychopharmacol (Berlin) 165: 222-228.
53. Meda Pharmaceuticals (2008). Sonata SPC (online). Available at http://www.emc.medicines.org.uk/ (accessed July 2008 ).
54. Monti JM, Attali P., Monti D., Zipfel A., de la Giclais B., Morselli PL (1994) Zolpidem and rebound insomnia-a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 27: 166-175.
55. Monti JM, Monti D., Estevez F., Giusti M. (1996) Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharm 11: 255-263.
56. Najib J. (2006) Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clinical Therapy 28: 491-516.
57. Ngen CC, Hassan R. (1990) A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazapam 20 mg in insomnia. Int Clin Psychopharma 5: 165-171.
58. Noble S., Langtry HD, Lamb HM (1998) Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 55: 277-302.
59. Noguchi H., Kitazumi K., Mori M., Shiba T. (2002) Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. Eur J Pharmacol 434: 21-28.
60. Nutt D. (2006) GABAA receptors: subtypes, regional distribution, and function. Journal of Clinical Sleep Medicine 2: S7 - S11.
61. Nutt DJ, Besson M., Wilson SJ, Dawson GR, Lingford-Hughes AR (2007) Blockade of alcohol's amnestic activity in humans by an a5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 53: 810-820.
62. Perlis ML, McCall WV, Krystal AD, Walsh JK (2004) Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiat 65: 1128-1137.
63. Petroski RE, Pomeroy JE, Das R., et al. (2006) Indiplon is a high-affinity positive allosteric modulator with selectivity for α1 subunit-containing receptors. J Pharmacol Exp Ther 317: 369-377.
64. Pirker S., Schwarzer C., Wieselthaler A., Sieghart W., Sperk G. (2000) GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neurosci 101: 815-850.
65. Pollack M., Kinrys G., Krystal A., et al. (2008) Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives in General Psychiatry 65: 551-562.
66. Ponciano E., Freitas F., Camara J., Faria M., Barreto M., Hindmarch I. (1990) A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin Psychopharmacol 5 (Suppl 2). 69-77.
67. Pritchett DB, Seeburg PH (1990) Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 54: 1802-1804.
68. Rosenberg R., Caron J., Roth T., Amato D. (2005) An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Medicine 6: 15-22.
69. Roth T. (2007) Insomnia: definition, prevalence, etiology, and consequences. Journal of Clinical Sleep Medicine 3 (5 Suppl). S7 - S10.
70. Roth T., Jaeger S., Jin R., Kalsekar A., Stang PE, Kessler RC (2006 a) Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. Biological Psychiatry 60: 1364-1371.
71. Roth T., Soubrane C., Titeux L., Walsh JK (2006 b) Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 7: 397-406.
72. Roth T., Walsh JK, Krystal A., Wessel T., Roehrs TA (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6: 487-495. (Pubitemid 41671203)
73. Rudolph U., Crestani F., Benke D., et al. (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401: 796-800.
74. Rudolph U., Möhler H. (2004) Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Ann Rev Pharmacol 44: 475-498.
75. Sanna E., Busonero F., Talani G., et al. (2002) Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. Eur J Pharmacol 451: 103-110.
76. Sanofi-Aventis. (2007) Ambien (Zolpidem Tartrate) Tablets for Oral Administration Prescribing Information. Bridgewater, NJ: Sanofi-Aventis.
77. Sanofi Aventis (2008 a) Stilnoct SPC, http://www.emc.medicines.org.uk (accessed July 2008).
78. Sanofi-Aventis (2008 b) Zimovane SPC, http://www.emc.medicines.org.uk (accessed July 2008).
79. Saper CB, Cano G., Scammell TE (2005) Homeostatic, circadian, and emotional regulation of sleep. J Comput Neurosc 493: 92-98.
80. Savi MM, Huang S., Furtmüller R., et al. (2008) Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists ? Neuropsychopharmacol 33: 332-339.
81. Scharf M. (2006) Eszopiclone for the treatment of insomnia. Expert Opin Pharmaco 7: 345-356.
82. Scharf M., Erman M., Rosenberg R., et al. (2005) A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 28: 720-727.
83. Scharf MB, Roth T., Vogel GW, Walsh JK (1994) A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiat 55: 192-199.
84. Sepracor. (2007) Lunesta (Eszopiclone) Tablets Prescribing Information. Marlborough, MA: Sepracor Inc.
85. Sieghart W. (2006) Structure, pharmacology, and function of GABAA receptor subtypes. Adv Pharmacol 54: 231-263.
86. Sivertsen B., Omvik S., Pallesen S., et al. (2006) Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. Journal of American Medical Association 295: 2851-2858.
87. Smith GB, Olsen RW (1995) Functional domains of GABAA receptors. Trends Pharmacol Sci 16: 162-168.
88. Staner L., Ertlé S., Boeijinga P., et al. (2005) Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berlin) 181: 790-798.
89. Stewart R., Besset A., Bebbington P., et al. (2006) Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 29: 1391-1397.
90. Stone BM, Turner C., Mills SL, et al. (2002) Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. Brit J Clin Pharmacol 53: 196-202.
91. Szuba MP, Kloss JD, Dinges DF (eds) (2003) Insomnia Principles and Management. Cambridge: Cambridge University Press.
92. Tobler I., Kopp C., Deboer T., Rudolph U. (2001) Diazepam-induced changes in sleep: role of the α1 GABAA receptor subtype. P Nat Acad Sci USA 98: 6464-6469.
93. Tsutsui S., et al. for the Zolpidem Study Group (2001) A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia. J Intl Med Res 29: 163-177.
94. van Rijnsoever C., Täuber M., Choulli MK, et al. (2004) Requirement of alpha 5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci 24: 6785-6790.
95. Vermeeren A., Riedel WJ, van Boxtel MP, Darwish M., Paty I., Patat A. (2002) Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 25: 224-231.
96. Wafford KA, Ebert B. (2008) Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 7: 530-540.
97. Walsh JK, Krystal AD, Amato DA, et al. (2007) Nightly treatment of primary insomnia with eszopiclone for six months: Effect on sleep, quality of life, and work limitations. Sleep 30: 959-968.
98. Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW (2000 a) Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23: 17-21.
99. Walsh JK, Roth T., Randazzo A., et al. (2000 b) Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23: 1087-1096.
100. Walsh JK, Soubrane C., Roth T. (2008) Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriat Psychiat 16: 44-57.
101. Wang F., Xu Z., Ren L., Tsang SY, Xue H. (2008) GABA(A) receptor subtype selectivity underlying selective anxiolytic effect of baicalin. Neuropharmacol 55: 1231-1237.
102. Ware JC, Walsh JK, Scharf MB, Roehrs T., Roth T., Vogel GW (1997) Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 20: 116-125.
103. Wegner F., Deuther-Conrad W., Scheunemann M., et al. (2008) GABAA receptor pharmacology of fluorinated derivatives of the novel sedative-hypnotic pyrazolopyrimidine indiplon. Eur J Pharmacol 580: 1-11.
104. Weinling E., McDougall S., Andre F., Bianchetti G., Dubruc C. (2006) Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol 20: 397-403.
105. Weissman MM, Greenwald S., Niño-Murcia G., Dement WC (1997) The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiat 19: 245-250.
106. Zammit GK, McNabb LJ, Caron J., Amato DA, Roth T. (2004) Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 20: 1979-1991.